PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
402.37%
G&A growth while AVXL reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Other expenses growth while AVXL reduces costs. John Neff would investigate differences.
547.73%
Operating expenses growth above 1.5x AVXL's 78.24%. Michael Burry would check for inefficiency.
547.73%
Total costs growth above 1.5x AVXL's 78.24%. Michael Burry would check for inefficiency.
3.95%
Interest expense growth while AVXL reduces costs. John Neff would investigate differences.
-96.03%
D&A reduction while AVXL shows 21.47% growth. Joel Greenblatt would examine efficiency.
-2633.53%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-468.26%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
6409.86%
Other expenses growth above 1.5x AVXL's 146.84%. Michael Burry would check for concerning trends.
-429.59%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-75.15%
Tax expense reduction while AVXL shows 99.26% growth. Joel Greenblatt would examine advantage.
-263.73%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-197.18%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-197.18%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
22.83%
Share count reduction below 50% of AVXL's 3.01%. Michael Burry would check for concerns.
22.83%
Diluted share change of 22.83% while AVXL is stable. Bruce Berkowitz would verify approach.